News

Artificial intelligence (AI) is not only transforming drug discovery but also revolutionizing multiple aspects of the life sciences industry. At the MedCity News INVEST Digital Health conference, industry experts discussed how AI can address pain points for biopharmaceutical companies beyond just identifying drug targets.

One area where AI can make a significant impact is in clinical trial management. Steve Prewitt, Senior Vice President and Global Head of Digital Innovation at Sumitomo Pharma Americas, highlighted the lack of effective tools for designing clinical trials and improving study outcomes. He cited the example of a Sumitomo study that faced challenges in recruiting adolescent patients for an overnight stay for testing a schizophrenia drug. Prewitt emphasized the need for AI-driven solutions to optimize clinical trial strategies and enhance patient recruitment.

Cost is another major concern in clinical trials. Prewitt stated that the primary cost lies in the elapsed time of the trial, rather than patient recruitment. Sumitomo Pharma Americas endeavors to shorten trial timelines by identifying doctors with access to specific patient populations and conducting patient recruitment analysis to expedite the process.

Massive Bio, a company utilizing AI, focuses on matching cancer patients with appropriate clinical trials. Selin Kurnaz, CEO and co-founder, shed light on the significant financial burden associated with finding the right patient for a trial, especially for biomarker-based studies. She revealed that some pharmaceutical companies spend up to million per patient in studies requiring rare biomarkers. Massive Bio aims to significantly reduce the time required for patient prescreening, which can currently take up to 25 minutes, by leveraging AI technology.

Sorcero, a leading AI platform in the life sciences sector, provides analysis and insights for decision-making in areas such as regulatory affairs and market access. CEO Dipanwita Das emphasized the need for the life sciences industry to learn from the retail sector’s data-driven approach. By leveraging data from various sources like electronic health records and peer-reviewed articles, Sorcero aims to provide life sciences companies with actionable insights similar to retailers’ understanding of customer preferences.

In conclusion, AI is emerging as a game-changer in the life sciences industry, not only in drug discovery but also in addressing pain points such as optimizing clinical trials, reducing costs, and providing valuable insights. Collaborating with AI platforms like Sorcero and utilizing advanced technologies like Massive Bio’s patient matching system is crucial for biopharmaceutical companies to enhance their operations and deliver improved healthcare outcomes.

Sources:
– MedCity News INVEST Digital Health conference
– https://medcitynews.com/2021/04/artificial-intelligence-clinical-trials-life-sciences/
– https://www.sorcero.com/
– https://massivebio.com/

The post Artificial Intelligence Revolutionizing the Life Sciences Industry: Solving Pain Points for Biopharmaceutical Companies appeared first on Fagen Wasanni Technologies.